MedTrace Logo

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07023627 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-05-08

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Conditions

Interventions

DRUG

INCB123667

Administered orally twice daily (BID).

Sponsors & Collaborators

  • ENGOT Foundation

    collaborator UNKNOWN

  • GOG Foundation

    collaborator NETWORK

  • Incyte Corporation

    lead INDUSTRY

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-12
Primary Completion
2027-04-27
Completion
2027-10-24
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Japan
  • Puerto Rico
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07023627 on ClinicalTrials.gov